IceCure Medical (ICCM) EBITDA Margin (2020 - 2026)

IceCure Medical (ICCM) has reported EBITDA Margin for 7 consecutive years, with 487.76% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA Margin fell 15700.0% year-over-year to 487.76% in Q2 2026; TTM through Jun 2026 was 423.69%, a 14538.0% decrease from a year earlier, with the FY2025 full-year figure at 446.7%, down 3024.0% from the prior year.
• EBITDA Margin was 487.76% for Q2 2026 at IceCure Medical, up from 466.19% in the prior quarter.
• Over five years, EBITDA Margin peaked at 1260.86% in Q3 2023 and troughed at 272.11% in Q4 2023.
• A 5-year average of 533.53% and a median of 497.83% in 2025 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin jumped 61401 bps in 2023 and slumped 61237 bps in 2024, its largest moves.
• Over 5 years, EBITDA Margin stood at 418.74% in 2022, then sank by 35 bps to 272.11% in 2023, then soared by 90 bps to 517.14% in 2024, then tumbled by 36 bps to 329.63% in 2025, then soared by 48 bps to 487.76% in 2026.
• The last three EBITDA Margin figures came in at 487.76% (Q2 2026), 466.19% (Q1 2026), and 329.63% (Q4 2025), per Business Quant data.